PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced it will present at two upcoming investor conferences in November, highlighting its growing pipeline of T cell–engaging bispecific antibodies for solid tumors.
The company will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston from November 10–12, where CEO management will host a fireside chat on Monday, November 10, at 3:00 PM ET, followed by one-on-one meetings. Context will also present at the Stifel 2025 Healthcare Conference in New York, scheduled for November 11–13, with a presentation on Wednesday, November 12, at 10:00 AM ET.
A live webcast of the Boston fireside chat will be available via the News and Events section of Context’s investor relations website, with a replay accessible for 90 days.
Headquartered in Philadelphia, Context Therapeutics is advancing a portfolio of T cell–engaging bispecific antibodies targeting Claudin 6 (CTIM-76), Mesothelin (CT-95), and Nectin-4 (CT-202). The company aims to expand immunotherapy options for patients with difficult-to-treat solid tumors.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.